Skip to main content
. 2019 Nov 7;55(3):641–648. doi: 10.1038/s41409-019-0731-x

Table 3.

Toxicities, adverse events, and malignancy relapse

Toxicities and adverse events N = 26/79 (32.9%)
Infections 4 (5)
 Fungal infection 2
 Bacterial/viral infection 2
Cytopenia 14 (17.7)
 Anemia 3
 Leukopenia 2
 Thrombocytopenia 5
 Combinations 4
Others 8 (10.1)
 Renal impairment 3
 Hepatic impairment 3
 Hypertension 1
 Edema 1
Action
 Dose reduction 14 (17.7)
 Temporary suspension 2 (2.5)
 Discontinuation 3 (3.7)
 No actions/Others 7 (8.8)
Malignancy relapse 1 (1.2)